Abstract
Acute restraint stress (ARS) for 3 hours causes CORT elevation in venous blood, which is accompanied by Fos up-regulation in the paraventricular nucleus (PVN) of male C57BL/6 mice. CORT elevation by ARS is attenuated in PACAP-deficient mice, but unaffected in PAC1-deficient mice. Correspondingly, Fos up-regulation by ARS is greatly attenuated in PACAP-deficient mice, but much less so in PAC1-deficient animals. We noted that both PACAP- and PAC1-deficiency greatly attenuate CORT elevation after ARS when CORT measurements are performed on trunk blood following euthanasia by abrupt cervical separation: this latter observation is of critical importance in assessing the role of PACAP neurotransmission in ARS, based on previous reports in which serum CORT was sampled from trunk blood. Seven days of chronic restraint stress (CRS) induces non-habituating CORT elevation, and weight loss consequent to hypophagia, in wild-type male C57BL/6 mice. Both CORT elevation and weight loss following seven day CRS are severely blunted in PACAP-deficient mice, but only slightly in PAC1 deficient mice. However, longer periods of daily restraint (14–21 days) resulted in sustained weight loss and elevated CORT in wild-type mice, and these effects of long-term chronic stress were attenuated or abolished in both PACAP- and PAC1-deficient mice. We conclude that while a PACAP receptor in addition to PAC1 may mediate some of the PACAP-dependent central effects of acute restraint stress and short-term (<7 days) chronic restraint stress on the HPA axis, the PAC1 receptor plays a prominent role in mediating PACAP-dependent HPA axis activation, and hypophagia, during long-term (>7 days) chronic restraint stress.
Keywords: acute psychogenic stress, chronic psychogenic stress, HPA axis, pituitary adenylate cyclase-activating polypeptide, PAC1 receptor, restraint
Introduction
PACAP neurotransmission has been linked to brain circuits whose chronic activation is hypothesized to underlie HPA axis activation due to psychogenic stress (Agarwal et al., 2005; Dore et al., 2013; Grinevich et al., 1997; Norrholm et al., 2005). PACAP-deficient mice were first reported to be less anxious than their wild-type counterparts, based on elevated plus, emergence and novel object tests, in 2001 (Hashimoto et al., 2001). PACAP is also linked to the effects of chronic stress in triggering depressive and anxious behaviors. For example, increased forced swim test immobility and decreased social interaction occurring after 14 days of social defeat in wild-type C57BL/6 mice, indicative of a behaviorally depressed phenotype, are absent in PACAP-deficient mice (Lehmann et al., 2013). In the rat, a series of reports has highlighted a potential role of PACAP neurotransmission in anxious behavior emerging during a chronic (seven-day) variate stress protocol (Hammack et al., 2009; Hammack et al., 2010; Kocho-Schellenberg et al., 2014; Roman et al., 2014). Furthermore, while HPA axis activation following psychogenic stress (i.e. chronic social defeat, acute restraint stress, open field exploration) is decreased in PACAP-deficient mice, CORT elevation following acute systemic stressors (hypoglycemia, lipopolysaccharide administration, or cold stress) is not (Lehmann et al., 2013; Stroth and Eiden, 2010; Stroth et al., 2011a; Stroth et al., 2011b; Tsukiyama et al., 2011). These studies implicate PACAP and its receptor(s) as possible targets in therapy for stress-related depression, and, along with recent clinical data (Ressler et al., 2011), potentially for depressive behavioral effects occurring in post-traumatic stress disorder (Hammack et al., 2012). However, more information derived from animal models for stress-related depression is required, along with additional clinical information, to fully implicate PACAP and its receptor(s) as drug targets for the treatment of depression or post-traumatic stress disorder (PTSD).
We sought to generalize the hypothesis that PACAPergic circuitry in the brain contributes to sustained activation of the HPA axis during chronic stress, by extending our studies of the effects of PACAP deficiency on chronic social stress (social defeat) to a second mild chronic psychogenic stressor, restraint (Hayashi et al., 2014; Kwon et al., 2006), that does not depend on social interaction. The PACAP receptor, PAC1, has been implicated in transducing the peripheral effects of PACAP on the adrenal medulla in both acute and chronic stress due to either psychogenic or systemic stressors in mice (Stroth and Eiden, 2010; Stroth et al., 2011a; Stroth et al., 2013; Stroth et al., 2011b). Both PACAP and the PAC1 receptor are also implicated in the anxiogenic effects of PACAP during chronic variate stress, mediated at the level of the extended amygdala, in the rat (Hammack et al., 2010; Roman et al., 2014). The studies reported here include an assessment of the effects of both PACAP and PAC1 deficiency on activation of the HPA axis following either acute or chronic restraint, and on the depressive behaviors induced by chronic restraint.
Materials and Methods
Animals
All experiments were conducted using male C57BL/6N wild-type and C57BL/6N PACAP-deficient mice, and male C57BL/6 wild-type and PAC1-deficient C57BL/6 mice, 8–10 weeks of age, generated through an in-house breeding program in accordance with NIH guidelines and standards. PAC1-deficient mice were genotyped as approximately 82% N/18%J as assessed at multiple loci at which J and N sub-strains differ, and hence each deficient line (PACAP and PAC1) was paired with congenic control (wild-type) mice. All mice were individually housed 24 hours (acute stress experiments) or seven days (chronic stress experiments) under a 12-hour light/12-hour dark cycle (lights off at 6 pm) with food and water ad libitum prior to experimental testing during the light phase of the cycle. Mice were randomly assigned to each experimental group. All experiments were approved by the NIMH Institutional Animal Care and Use Committee (ACUC) and conducted in accordance with the NIH guidelines. Generation of PACAP knock-out mice, and PAC1 knock-out mice, have been described previously, with each line back-crossed on to C57BL/6 as described above (Hamelink et al., 2002a; Otto et al., 2001).
Lipopolysaccharide (LPS) administration
Lipopolysaccharide (LPS) challenge was conducted as previously described (Ait-Ali et al., 2010; Lehmann et al., 2013). Briefly, animals were transported to the test room in their home cages and individually housed for 12 hours during the dark phase of the light cycle. The following day, three hours into the light phase, mice were injected intraperitoneally with LPS (4 μl/g body weight, of a 0.25 mg/ml solution in saline) from E. coli serotype 0.111:B4 (Sigma-Aldrich, St. Louis, MO), or an equivalent volume of saline. After three hours, mice were transferred into a DecapiCone (DecapiCones®, Braintree Scientific Inc, USA), rapidly killed by decapitation with sharp surgical scissors, and trunk blood collected and processed according to procedures described below.
Acute restraint stress
Acute restraint stress was carried out as previously described (Stroth and Eiden, 2010). In brief, individually housed animals were transported to the test room in their home cages as described in the aforementioned methods. Mice were then restrained in a DecapiCone with all limbs positioned flat underneath the body to minimize physical pain. The large end of the tube was then rolled shut and secured with adhesive tape. The DecapiCones used were also previously perforated for adequate ventilation, with the tip of the cone removed to allow unobstructed breathing. The restrained mice were then placed back into the home cage for three hours. The control, unstressed cohort of mice was left undisturbed in the test room throughout the entire duration of the experiments. Trunk blood was then collected according to the procedures described below, in a hood providing insulation of sound and odor from the rest of the room. For collection of tail blood, all mice were transported to the test room, allowed to acclimatize for 30 minutes and handled briefly (~two minutes) for a duration of three days, to achieve habituation to handling stress prior to restraint studies and blood sampling. The mice were then restrained for three hours on day four, as described above, released from the DecapiCone, and returned to the home cage prior to having tail vein blood sampled within five minutes of release. Unstressed control counterparts were subjected to identical handling and habituation procedures and remained undisturbed in their home cages for three hours prior to tail blood collection. All experiments were carried out between 11 a.m. and 3 p.m. (between five and nine hours into the twelve-hour light phase).
Chronic restraint stress for seven days
Three days prior to initiation of stress all mice were transported to the behavioral testing room, allowed to acclimatize for 30 minutes and habituated to handling for three days as described above. On the last day of habituation, all mice had tail vein blood sampled as described below. On the first day of restraint stress, mice were transported to the test room in their home cages, acclimatized for 30 minutes and restrained for two hours according to the procedures described above. The mice were then released from the restraint, sampled for tail vein blood (within five minutes) or handled for sham blood collection (~ two minutes) on the days that did not require blood collection. The mice were then returned to their home cages and transported to the colony room. The procedure followed on day one was continued for 7 consecutive days with blood collections made on 1, 4 and 7 days of restraint stress. All experiments were carried out between 11 a.m. and 3 p.m. (between five and nine hours into the twelve-hour light phase).
Chronic restraint stress for twenty-one days
Three days prior to initiation of stress, all mice were transported to the behavioral testing room, allowed to acclimatize for 30 minutes and habituated to handling for three days as described above. On the last day of habituation, all mice had tail vein blood sampled as described below. On the first day of restraint stress, all mice were transported to the test room in their home cages, acclimatized for 30 minutes and restrained (restraint group) or allowed to remain undisturbed in their home cages (unrestrained control group) for two hours according to the procedures described above. The mice were then sampled for tail vein blood (within five minutes of release from restraint, or immediately upon removal from the home cage in the case of unrestrained controls). All mice were handled for sham blood collection (~ two minutes) on the days that did not require blood collection. The mice were then returned to their home cages and transported to the colony room. The procedure followed on day one was continued for 21 consecutive days with blood collections made on 1, 7, 14 and 21 days of restraint stress. All experiments were carried out between 11 a.m. and 3 p.m. (between five and nine hours into the twelve-hour light phase).
Body weight and food consumption
All mice (control and stress group) were weighed daily throughout the entire duration of experimental testing. Percentage weight loss was calculated as the weight of the mouse on the indicated day following initiation of the chronic restraint protocol, divided by the weight of the mouse on day zero prior to initiation of the chronic restraint protocol, times 100. Food consumption of standard chow was determined daily, in some experiments, by weighing the food pellets (in grams) and determining the amount of food consumed by each mouse over a 24 hour period.
Blood sampling and determination of plasma corticosterone levels
For tail vein blood sampling, sharp surgical scissors were used to remove ~1–2 mm of the most distal portion of the tail while the mouse was loosely held but not restrained by the tail. The tail was gently massaged to stimulate blood flow, and blood (approximately 20 μl) was collected directly into heparinized 40 mm microhematocrit tubes (SafeCrit, IRIS, Inc, MA). Blood flow was stopped by cauterizing the wound with silver nitrate applicator swabs (GF Health Products) and applying gentle finger pressure before the animal was returned to its home cage. Plasma was then collected by centrifugation (Micro-hematocrit centrifuge, IRIS, Inc, MA) and stored at −80° C. For trunk blood collections, mice were decapitated while still restrained or transferred rapidly from their home cages, paced into a DecapiCone and decapitated within 20 seconds with the use of a sharp heavy scissors. The collected trunk blood was allowed to coagulate at room temperature for one hour, chilled on ice, centrifuged for 10 min, and the supernatant re-centrifuged for five minutes at 10,000 × g to collect serum. Corticosterone levels in serum was then determined using the DetectX corticosterone ELISA kit (Arbor Assays, Michigan, USA) according to the manufacturer’s instructions. In some experiments, corticosterone levels were measured by radioimmunoassay as previously described (Lehmann et al., 2013), and no systematic differences between the results obtained in either assay system were noted.
Home-cage monitoring of locomotor activity
Naïve mice individually housed for at least 24 hours, and not previously subjected to any stress paradigms or behavioral testing, were transported to the behavioral testing room and placed into the home cage monitoring system (CleverSys Inc). Mice were transferred to cages containing bedding from the home cage, and side capture video recording carried out for 23 hours. Distance traveled per 30 min over a 23 hour period was derived using the standard master settings file provided by the manufacturer.
Immunohistochemistry
Mice restrained according to the procedures described above, or left undisturbed in their home cages for three hours, were overdosed with Avertin, and immediately transcardially perfused with ice-cold saline supplemented with 5 mM EGTA followed by ice-cold 4% paraformaldehyde (PFA) prepared in 0.1 M phosphate buffer (pH 7.4). Following the perfusion, the brains were removed, post fixed for an additional 24 hours with 4% PFA and then coronally sectioned with a vibratome at a thickness of 35 μm. Free-floating sections were then washed and permeabilised with Tris-buffered saline (TBS) supplemented with 0.5% Triton X-100, blocked with 10% normal goat serum and incubated overnight at 4°C under gentle agitation with primary Fos antibody (1:3000, Ab-5, Calbiochem). The sections were then incubated for a further two hours at room temperature with Alexa 488-conjugated anti-rabbit-IgG (1:300; Invitrogen) secondary antibody, prior to being mounted in Vectashield mounting medium with DAPI (catalog number H-1200; Vector Laboratories). Representative sections of the paraventricular nucleus (PVN) of the hypothalamus (2–4 sections, bregma −0.70 to −0.94) were then visualized for fluorescence using a confocal microscope (Zeiss LSM 510). Images were converted to 16-bit greyscale and the number of Fos positive cells quantitated using the NIH ImageJ software. Images were thresholded to highlight Fos positive nuclei and subjected to “Analyze Particles” by setting “size (pixel ^2)” as 10-infinity and “circularity” as 0.0–1.00. Fluorescence intensity for Fos IR (immunoreactivity) in PVN was also quantified and compared across the groups.
Statistical Analysis
Data were analyzed for statistical significance by two-way ANOVA followed by Bonferroni post-hoc test using SigmaPlot 11.0. Repeated measures were conducted using STATISTICA.
Results
PACAP but not PAC1 deficiency attenuates CORT elevation, with corresponding effect on PVN Fos induction, in ARS
Elevation in CORT levels upon acute restraint stress (ARS) for three hours, as previously reported, was significantly less in PACAP-deficient, compared to wild-type mice (Figure 1A, gene effect: F(1,37)=17.414, p<0.001; stress effect: F(1,37)=160.521, p<0.001; gene x stress: F(1, 37)=5.294, p=0.027; two-way ANOVA followed by Bonferroni post-hoc test to compare PACAP+/+ vs PACAP−/− within RS, p<0.001), but has no effect on circulating CORT in PAC1-deficient mice (Figure 1B, gene effect: F(1,40)=0.0071, p=0.933).
The blunting effect of PACAP deficiency on serum CORT elevation when sampled from the tail vein, while significant, was less than the effect on CORT elevation previously reported, when trunk blood was sampled (Lehmann et al., 2013; Stroth and Eiden, 2010; Tsukiyama et al., 2011). We repeated three hour ARS in both PACAP- and PAC1-deficient mice, and their wild-type counterparts, with collection of trunk blood at time of euthanasia. Both PACAP- and PAC1-deficient mice showed a significant attenuation of CORT elevation, when sampled from trunk blood, compared to control mice (Supplementary Figure 1A, gene effect: F(1, 37)=66.757, p<0.001; stress effect: F(1,37)=137.51, p<0.001; gene x stress: F(1, 37)=56.968, p<0.001; two-way ANOVA followed by Bonferroni post-hoc test to compare PACAP+/+ vs PACAP−/− within RS, p<0.001). Supplementary Figure 1B, gene effect: F(1,36)=24.157, p<0.001, stress effect: F(1,36)=100.989, p<0.001; gene x stress: F(1,36)=5.829, p=0.021; two-way ANOVA followed by Bonferroni post-hoc test to compare PAC1+/+ vs PAC1−/− within RS, p<0.001). Furthermore, as previously reported for PACAP-deficient mice, PAC1-deficient mice showed no attenuation of CORT elevation after LPS challenge, even when trunk blood is collected following decapitation (data not shown). In the remaining experiments reported here, CORT levels were assessed following tail vein, rather than trunk blood, sampling.
Given the apparent lack of effect of PAC1 receptor utilization on CORT elevation following ARS, we focused on central effects of PACAP and PAC1 deficiency unlikely to be affected via the splanchnic nerve. CRH-elaborating neurons of the paraventricular nucleus (PVN) of the hypothalamus transduce both systemic and psychogenic stress responses, whether acute or chronic, in mammals. Restraint stress increases Fos expression in CRF-expressing neurons of the PVN, and this increase is blunted in PACAP-deficient mice (Tsukiyama et al., 2011). Using Fos protein expression as an index of activation of these neurons, we examined PVN neuronal activation after ARS, in PACAP- and PAC1-deficient mice compared to their wild-type counterparts, after three hours of restraint (Figure 2). Both the number of Fos-positive neurons in the PVN, and the relative intensity of Fos expression within them, was dramatically increased by three hour restraint (Figure 2A). Activation was decreased more than 50% in PACAP-deficient mice, but less than 25% in PAC1-deficient mice (Figure 2B, two-way ANOVA to compare the number of Fos-positive neurons, gene x stress: F(1,16)=95.281, p<0.001 for PACAP mice; F(1,20)=12.117, p=0.003 for PAC1 mice. For relative intensity of Fos expression, gene x stress: F(1,16)=218.233, p<0.001 for PACAP mice; F(1,20)=12.662, p=0.002 for PAC1 mice).
PACAP and PAC1 deficiency differentially affect CORT elevation and weight reduction as a function of chronic stress exposure across a 7-day period
If the effects of PACAP neurotransmission at the level of the PVN during stress responding are exerted largely on CRH biosynthesis subsequent to neuronal activation, as previously suggested by Stroth et al. (Stroth et al., 2011b), the effects of PACAP deficiency on sustained CORT elevation during chronic stress would be predicted to become progressively more prominent, as initially reported by our laboratory in the context of chronic social defeat (Lehmann et al., 2013). We measured CORT levels prior to the onset of chronic restraint stress (CRS), and on days 1, 4, and 7 during one week of daily (two hours per day) restraint (see Figure 3A for experimental design). In PACAP-deficient mice, there was a significant diminution of CORT elevation measured immediately following cessation of the restraint session, which increased as a function of repeated restraint across the seven day period (Figure 3B, PACAP+/+ vs PACAP −/−, F(4,37)=28.10, p<0.001, repeated measures one-way ANOVA followed by Bonferroni post-hoc test, p>0.05 on day 0, however p<0.001 on day 1, or 4 or 7). In contrast, elevation of CORT following restraint was not significantly altered in PAC1-deficient mice until day 7 of chronic restraint (Figure 3C, PAC1 +/+ vs PAC1 −/−, F(4, 13)=1.697, p=0.210, repeated measures one-way ANOVA followed by Bonferroni post-hoc test, p>0.05 on day 0, 1, and day 4; on day 7, p=0.043).
The effects of seven-day CRS on CORT elevation were paralleled by weight loss in wild-type, but not PACAP-deficient mice (Figure 3D, p<0.001, Student’s t-test), while in PAC1-deficient mice only a modest protection from the effects of restraint on weight loss was observed (Figure 3E, p=0.039, Student’s t-test).
In order to control for potential effects of differential locomotor activity, or metabolic effects, on body weight during the seven-day CRS period, locomotor activity was measured in both PACAP-deficient and PAC1-deficient mice and their wild-type counterparts. As reported previously, PACAP-deficient mice were considerably more active during a 23-hr period than wild-type mice (p<0.001, Mann-Whitney rank sum test, Figure 4), while locomotor activity of PAC1-deficient mice was similar to their wild-type counterparts (p=0.106). Thus, greater weight loss in PAC1-deficient, compared to PACAP-deficient mice, could not be attributed to a higher level of activity of these mice. Furthermore, direct measurement of food intake in wild-type mice subjected to stress demonstrated that weight loss was a direct consequence of hypophagia, and this stress-related decrease in food intake was not observed in PACAP-deficient animals (Figure 5, gene effect: F(1,57)=37.338, p<0.001; stress effect: F(1,57)=4.941, p=0.03; two-way ANOVA followed by Bonferroni post-hoc test to compare NRS vs RS, p=0.048 for PACAP +/+, p=1 for PACAP −/−).
PACAP and PAC1 deficiency affect CORT elevation and weight reduction as a function of chronic stress exposure across a 21-day period
HPA axis elevation and weight loss as a consequence of seven days of continuous daily restraint was not significantly attenuated in PAC1-deficient mice until day seven, and even at day seven represented a significantly smaller effect of genotype for PAC1-deficiency compared to PACAP-deficiency (see Figure 3). Since previous reports indicate that some behavioral effects of chronic stress emerge more robustly at longer periods than one week in some rodent models (Strekalova et al., 2011), additional experiments were performed over a longer period of chronic stress, and the effects of genotype (PACAP and PAC1 deficiency) were examined (Figure 6A). In these experiments, unrestrained mice of all genotypes were maintained under identical conditions (daily transport to behavioral stimulus room, but without restraint) so that comparisons of both body weight and CORT levels would be tightly temporally controlled. By day 14 of restraint, and continuing for an additional week, the effect of PACAP deficiency on CORT elevation progressed from a significant decrease compared to CORT levels in wild-type mice, but still a significant elevation compared to unrestrained mice, to a mild elevation upon restraint that was not significantly greater than CORT levels in unrestrained mice (Figure 6B; repeated measures two-way ANOVA, gene effect: F(3, 12)=37.631, p<0.001; stress effect: F(3, 12)=90.280, p<0.001; gene x stress: F(3, 12)=41.642, p<0.001. Bonferroni post-hoc test, PACAP +/+ vs PACAP −/− within RS, p<0.001 on day 7, day 14 and day 21; RS vs NRS within PACAP −/−, p=0.082 on day 7, p=0.135 on day 14, p=1 on day 21).
PAC1-deficient mice also showed a progressive attenuation of CORT elevation, in response to restraint, that was significantly less than CORT elevation following restraint in wild-type mice, but still significantly greater than CORT levels in unrestrained (control) wild-type mice maintained under otherwise identical conditions of husbandry during the three-week period of chronic restraint (Figure 6C; repeated measures two-way ANOVA, gene effect: F(3, 33)=15.234, p<0.001; stress effect: F(3, 33)=92.972, p<0.001; gene x stress: F(3, 33)=13.335, p<0.001. Bonferroni post-hoc test, PAC1 +/+ vs PAC1 −/− within RS, p<0.01 on day 7, p<0.001 on day 14 and day 21; RS vs NRS within PAC1−/−, p<0.001 on day 7, day 14 and day 21).
Both PACAP- and PAC1-deficient mice showed significant resistance to weight loss as a consequence of restraint over the last two weeks of the three-week chronic restraint period, albeit the effect of PAC1-deficiency was quantitatively less than that of PACAP deficiency (Figure 6D, repeated measures two-way ANOVA, gene effect: F(3, 28)=1.984, p=0.139; stress effect: F(3, 28)=20.688, p<0.001; gene x stress: F(3, 28)=9.332, p<0.001; Bonferroni post-hoc test PACAP +/+ vs PACAP −/− within RS, p<0.001 on day 7, p<0.01 on day 14 and day 21; RS vs NRS within PACAP−/−, p>0.05 on day 7, day 14 and day 21. Figure 6E, repeated measures two-way ANOVA, gene effect: F(3, 33)=8.213, p<0.001; stress effect: F(3, 33)=104.153, p<0.001; gene x stress: F(3, 33)=18.119, p<0.001. Bonferroni post-hoc test, PAC1 +/+ vs PAC1 −/− within RS, p<0.001 on day 7, day14 and day 21; RS vs NRS within PAC1−/−, p<0.001 on day 7, day 14 and day 21).
Discussion
A large body of evidence implicates the neurotransmitter PACAP in both peripheral and central neurotransmission underlying stress responding. The data presented in this report provides important new features of PACAP neurotransmission in stressor responding mediated centrally and peripherally, and in stressor responding initiated either by systemic stressors, or by psychogenic stressors.
The main findings of our report are that there is a requirement for PACAP, but not for PAC1 expression, in mediating HPA axis activation during ARS, and a major role for PACAP, with progressively greater involvement of PAC1, in mediating HPA axis activation, and hypophagia, during CRS. Hypophagia is considered an index of anhedonia/depression in mouse models (Lim et al., 2012), along with sucrose preference which could not however be measured in our study due to potential secondary effects on caloric intake and body weight.
Previous studies have convincingly demonstrated that PACAP is the ‘stress transmitter’ released by the splanchnic nerve during high-frequency stimulation occasioned by increased sympathetic outflow secondary to either systemic or psychogenic stress, and that the peripheral neurotransmitter actions of PACAP at the adrenomedullary synapse occur via engagement of the PAC1 receptor (Kuri et al., 2009; Stroth and Eiden, 2010; Stroth et al., 2013). Our results demonstrate that PAC1 receptor deficiency does not affect CORT secretion during ARS. The data do, however, uncover a mechanism for a PAC1-dependent, PACAP-dependent agonal effect on serum CORT elevation after ARS mediated peripherally by massive splanchnic disinhibition upon decapitation (Mravec et al., 2012; Popper et al., 1977). This must be accounted for in assessing both PACAP- and PAC1-dependence of the overall stress response in vivo. Specifically, we hypothesize that a PACAP- and PAC1-dependent increase in the biosynthesis of CORT within the adrenal cortex, and its release upon splanchnic disinhibition during decapitation, may cause misattribution of central versus peripheral mediation of stress responses within the HPA axis. Numerous experiments in both rats and mice are carried out via trunk blood sampling for CORT, on the assumption that agonal effects on CORT secretion, if they occurred, would be manifest in both stressed and unstressed cohorts (see, e.g. (Barnum et al., 2007)). Since this does not appear to be the case, blood sampling by tail vein rather than via collection of trunk blood in experiments examining the effects of neuropeptides including PACAP on both acute and chronic stress responding, may be preferred to avoid conflation of effects occurring during life, and agonal effects, on CORT secretion in such experiments.
The data presented here, in our view, argue for a major role of PACAP neurotransmission, likely at the level of the PVN, in supporting sustained HPA axis activation during chronic stress, and that this action is mediated by multiple PACAP receptors, with PAC1 being the dominant receptor for PACAP during prolonged chronic psychogenic stress. Determining which additional receptors are involved in earlier phases of PACAP-dependent stress response will require parallel studies with VPAC1- and VPAC2-deficient mice. It must also be remarked that the evidence in favor of a role of PACAP transmission at extrahypothalamic sites, via PAC1 receptor activation, in mediating anxiety associated with chronic variate stress, adduced mainly in rat experimental models, is quite strong (Hammack et al., 2009; Hammack et al., 2010). It will be imperative, in the near future, to establish whether the effects of chronic stress on anhedonia and anxiety, both associated with depression as clinically diagnosed, can be dissociated based on dependence on PAC1 receptor utilization, and on the region of the brain mediating these effects. PACAP effects on depression-related behaviors, such as hypophagia, may well be independent, both in terms of causality and circuitry, of PACAP effects on the HPA axis. However, the observed fact that PACAP and PAC1 receptor neurotransmission affect both offers a new avenue of opportunity to perform genetically-based regional lesions in PACAPergic circuitry in mouse brain to determine whether this is the case. Such studies may have the added virtue of defining more precisely what effects of PACAP neurotransmission are more likely to be adaptive, or maladaptive, in response to a given stressor, and thus provide a biological guide to the development of PACAP-related therapeutic approaches to depression and anxiety disorders.
Finally, we wish to provide a caveat, based on the results herein, of the hypothesis put forward by ourselves and others that PACAP neurotransmission is important in mediating the behavioral effects of psychogenic stress, but not systemic stress, because of a differential utilization of PACAPergic and non-PACAPergic circuits in activation of the HPA axis by each stressor modality (Hamelink et al., 2002b; Lehmann et al., 2013; Tsukiyama et al., 2011). The differential effect of PACAP on CORT elevation following an acute psychogenic (restraint), compared to a systemic (LPS) stressor is maintained whether CORT is measured in peripheral blood, or by sampling of trunk blood. However, this differential effect is far more modest when apparent agonal effects of trunk blood sampling are taken into account. Thus, it will be of considerable interest, in future experiments, to compare the robust dependence of chronic psychogenic stress on PACAP neurotransmission, to that of chronic, rather than acute systemic stress.
In summary, we have provided evidence that PACAP mediates the central effects of stress on sustained CORT elevation across the period of application of CRS, and that the PAC1 receptor plays an increasingly important role in transduction of PACAP signaling with longer periods of chronic stress. We believe these findings are of great translational significance for two reasons. First, the finding of a requirement for PACAP expression in the depressogenic effects of chronic stress in both chronic social defeat and chronic restraint stress (CRS) increases the likelihood that PACAP neurotransmission might be required for the depressive effects of chronic stress in humans. CRS presents a maximally robust and efficient test for in vivo screening of PACAP antagonists in treatment of behavioral disorders associated with chronic stress. Second, the requirement for PAC1 receptor expression in HPA responsiveness to chronic, but not acute psychogenic stress, and the apparently more penetrant genotypic effect of PACAP than of PAC1 deficiency, argues for further inquiry into the role(s) of the VPAC1 and VPAC2 receptors in mediating the neurotransmitter effects of PACAP during chronic psychogenic stress.
Supplementary Material
Acknowledgments
We acknowledge support from the National Institute of Health (NIMH) Intramural Research Program (1ZIAMH002386); the Brain and Behavior Foundation (NARSAD Young Investigator Award to Tomris Mustafa), and David Huddleston and Chang-Mei Hsu for assistance with management of mouse colonies, genotyping and conducting quantitative PCR.
Footnotes
Declaration of Interests:
The authors declare no conflicts of interest.
References
- Agarwal A, Halvorson LM, Legradi G. Pituitary adenylate cyclase-activating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: Evidence for PKA-mediated expression of the corticotropin-releasing hormone (CRH) gene. Brain Res Mol Brain Res. 2005;138:45–57. doi: 10.1016/j.molbrainres.2005.03.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ait-Ali D, Stroth N, Sen JM, Eiden LE. PACAP-cytokine interactions govern adrenal neuropeptide biosynthesis after systemic administration of LPS. Neuropharmacology. 2010;58:208–214. doi: 10.1016/j.neuropharm.2009.07.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Barnum CJ, Blandino P, Jr, Deak T. Adaptation in the corticosterone and hyperthermic responses to stress following repeated stressor exposure. J Neuroendocrinol. 2007;19:632–642. doi: 10.1111/j.1365-2826.2007.01571.x. [DOI] [PubMed] [Google Scholar]
- Dore R, Iemolo A, Smith KL, Wang X, Cottone P, Sabino V. CRF mediates the anxiogenic and anti-rewarding, but not the anorectic effects of PACAP. Neuropsychopharmacology. 2013;38:2160–2169. doi: 10.1038/npp.2013.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Grinevich V, Fournier A, Pelletier G. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on corticotropin-releasing hormone (CRH) gene expression in the rat hypothalamic paraventricular nucleus. Brain Res. 1997;773:190–196. doi: 10.1016/s0006-8993(97)01011-1. [DOI] [PubMed] [Google Scholar]
- Hamelink C, Lee H-W, Hsu C-M, Eiden LE. Role of protein kinases in neuropeptide gene regulation by PACAP in chromaffin cells--A pharmacological and bioinformatic analysis. Ann N Y Acad Sci. 2002a;971:474–490. doi: 10.1111/j.1749-6632.2002.tb04512.x. [DOI] [PubMed] [Google Scholar]
- Hamelink C, Tjurmina O, Damadzic R, Young WS, Weihe E, Lee H-W, Eiden LE. Pituitary adenylate cyclase activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis. Proc Natl Acad Sci USA. 2002b;99:461–466. doi: 10.1073/pnas.012608999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hammack SE, Cheung J, Rhodes KM, Schutz KC, Falls WA, Braas KM, May V. Chronic stress increases pituitary adenylate cyclase-activating peptide (PACAP) and brain-derived neurotrophic factor (BDNF) mRNA expression in the bed nucleus of the stria terminalis (BNST): roles for PACAP in anxiety-like behavior. Psychoneuroendocrinology. 2009;34:833–843. doi: 10.1016/j.psyneuen.2008.12.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hammack SE, Cooper MA, Lezak KR. Overlapping neurobiology of learned helplessness and conditioned defeat: implications for PTSD and mood disorders. Neuropharmacology. 2012;62:565–575. doi: 10.1016/j.neuropharm.2011.02.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hammack SE, Roman CW, Lezak KR, Kocho-Shellenberg M, Grimmig B, Falls WA, Braas K, May V. Roles for Pituitary Adenylate Cyclase-Activating Peptide (PACAP) Expression and Signaling in the Bed Nucleus of the Stria Terminalis (BNST) in Mediating the Behavioral Consequences of Chronic Stress. J Mol Neurosci. 2010;42:327–340. doi: 10.1007/s12031-010-9364-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hashimoto H, Shintani N, Tanaka K, Mori W, Hirose M, Matsuda T, Sakaue M, Miyazaki J-i, Niwa H, Tashiro F, Yamamoto K, Koga K, Tomimoto S, Kunugi A, Suetake S, Baba A. Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP) Proc Natl Acad Sci USA. 2001;98:13355–13360. doi: 10.1073/pnas.231094498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hayashi T, Ikematsu K, Abe Y, Ihama Y, Ago K, Ago M, Miyazaki T, Ogata M. Temporal changes of the adrenal endocrine system in a restraint stressed mouse and possibility of postmortem indicators of prolonged psychological stress. Leg Med (Tokyo) 2014;16:193–196. doi: 10.1016/j.legalmed.2014.03.005. [DOI] [PubMed] [Google Scholar]
- Kocho-Schellenberg M, Lezak KR, Harris OM, Roelke E, Gick N, Choi I, Edwards S, Wasserman E, Toufexis DJ, Braas KM, May V, Hammack SE. PACAP in the BNST Produces Anorexia and Weight Loss in Male and Female Rats. Neuropsychopharmacology. 2014;39:1614–1623. doi: 10.1038/npp.2014.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kuri BA, Chan SA, Smith CB. PACAP regulates immediate catecholamine release from adrenal chromaffin cells in an activity-dependent manner through a protein kinase C-dependent pathway. J Neurochem. 2009;110:1214–1225. doi: 10.1111/j.1471-4159.2009.06206.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kwon MS, Seo YJ, Shim EJ, Choi SS, Lee JY, Suh HW. The effect of single or repeated restraint stress on several signal molecules in paraventricular nucleus, arcuate nucleus and locus coeruleus. Neuroscience. 2006;142:1281–1292. doi: 10.1016/j.neuroscience.2006.07.027. [DOI] [PubMed] [Google Scholar]
- Lehmann ML, Mustafa T, Eiden AM, Herkenham M, Eiden LE. PACAP-deficient mice show attenuated corticosterone secretion and fail to develop depressive behavior during chronic social defeat stress. Psychoneuroendocrinology. 2013;38:702–715. doi: 10.1016/j.psyneuen.2012.09.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lim BK, Huang KW, Grueter BA, Rothwell PE, Malenka RC. Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens. Nature. 2012;487:183–189. doi: 10.1038/nature11160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mravec B, Bodnar I, Uhereczky G, Kvetnansky R, Palkovits M. Effect of lesions of A5 or A7 noradrenergic cell group or surgical transection of brainstem catecholamine pathways on plasma catecholamine levels in rats injected subcutaneously by formalin. General physiology and biophysics. 2012;31:247–254. doi: 10.4149/gpb_2012_029. [DOI] [PubMed] [Google Scholar]
- Norrholm SD, Das M, Legradi G. Behavioral effects of local microinfusion of pituitary adenylate cyclase activating polypeptide (PACAP) into the paraventricular nucleus of the hypothalamus (PVN) Regul Pept. 2005;128:33–41. doi: 10.1016/j.regpep.2004.12.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Otto C, Martin M, Wolfer DP, Lipp HP, Maldonado R, Schutz G. Altered emotional behavior in PACAP-type-I-receptor-deficient mice. Brain Res Mol Brain Res. 2001;92:78–84. doi: 10.1016/s0169-328x(01)00153-x. [DOI] [PubMed] [Google Scholar]
- Popper CW, Chiueh CC, Kopin IJ. Plasma catecholamine concentrations in unanesthetized rats during sleep, wakefulness, immobilization and after decapitation. J Pharmacol Exp Ther. 1977;202:144–148. [PubMed] [Google Scholar]
- Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K, Norrholm SD, Kilaru V, Smith AK, Myers AJ, Ramirez M, Engel A, Hammack SE, Toufexis D, Braas KM, Binder EB, May V. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature. 2011;470:492–497. doi: 10.1038/nature09856. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roman CW, Lezak KR, Hartsock MJ, Falls WA, Braas KM, Howard AB, Hammack SE, May V. PAC1 receptor antagonism in the bed nucleus of the stria terminalis (BNST) attenuates the endocrine and behavioral consequences of chronic stress. Psychoneuroendocrinology. 2014;47:151–165. doi: 10.1016/j.psyneuen.2014.05.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Strekalova T, Couch Y, Kholod N, Boyks M, Malin D, Leprince P, Steinbusch HM. Update in the methodology of the chronic stress paradigm: internal control matters. Behav Brain Funct. 2011;7:9. doi: 10.1186/1744-9081-7-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stroth N, Eiden LE. Stress hormone synthesis in mouse hypothalamus and adrenal gland triggered by restraint is dependent on pituitary adenylate cyclase-activating polypeptide signaling. Neuroscience. 2010;165:1025–1030. doi: 10.1016/j.neuroscience.2009.11.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stroth N, Holighaus Y, Ait-Ali D, Eiden LE. PACAP: a master regulator of neuroendocrine stress circuits and the cellular stress response. Ann N Y Acad Sci. 2011a;1220:49–59. doi: 10.1111/j.1749-6632.2011.05904.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stroth N, Kuri BA, Mustafa T, Chan SA, Smith CB, Eiden LE. PACAP controls adrenomedullary catecholamine secretion and expression of catecholamine biosynthetic enzymes at high splanchnic nerve firing rates characteristic of stress transduction in male mice. Endocrinology. 2013;154:330–339. doi: 10.1210/en.2012-1829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stroth N, Liu Y, Aguilera G, Eiden LE. Pituitary adenylate cyclase-activating polypeptide (PACAP) controls stimulus-transcription coupling in the hypothalamic-pituitary-adrenal axis to mediate sustained hormone secretion during stress. J Neuroendocrinol. 2011b;23:944–955. doi: 10.1111/j.1365-2826.2011.02202.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tsukiyama N, Saida Y, Kakuda M, Shintani N, Hayata A, Morita Y, Tanida M, Tajiri M, Hazama K, Ogata K, Hashimoto H, Baba A. PACAP centrally mediates emotional stress-induced corticosterone responses in mice. Stress. 2011;14:368–375. doi: 10.3109/10253890.2010.544345. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.